Autores: Llau, J. V. (Autor de correspondencia); Ferrandis, R.; Sierra, P.;
Hidalgo Martínez, Francisco Nicesio; Cassinello, C.; Gómez-Luque, A.; Quintana, M.; Amezaga, R.; Gero, M.; Serrano, A.; Marcos, P.
Resumen:
The infection by the coronavirus SARS-CoV-2, which causes the disease called COVID19, mainly causes alterations in the respiratory system. In severely ill patients, the disease oftenevolves into an acute respiratory distress syndrome that can predispose patients to a state ofhypercoagulability, with thrombosis at both venous and arterial levels. This predisposition presents a multifactorial physiopathology, related to hypoxia as well as to the severe inflammatoryprocess linked to this pathology, including the additional thrombotic factors present in many ofthe patients. In view of the need to optimise the management of hypercoagulability, the working groupsof the Scientific Societies of Anaesthesiology-Resuscitation and Pain Therapy (SEDAR) and ofIntensive, Critical Care Medicine and Coronary Units (SEMICYUC) have developed a consensus to establish guidelines for actions to be taken against alterations in haemostasis observedin severely ill patients with COVID-19. These recommendations include prophylaxis of venousthromboembolic disease in these patients, and in the peripartum, management of patients onlongterm antiplatelet or anticoagulant treatment, bleeding complications in the course of thedisease, and the interpretation of general alterations in haemostasis.
